Shmuel Tuvia

Shmuel Tuvia, Ph.D., is a senior biopharmaceutical executive who began his career in drug development in the 1990s. Shmuel previously served as Chief Development Officer at Ukko, a company that is focused on developing immunotherapies for food allergies. Prior to Ukko, Shmuel held a Chief Operations Officer role at Eloxx, where he developed a clinical candidate molecule, ELX-02 for the treatment of several genetic diseases such as Cystic Fibrosis and Rett Syndrome. He also served at Chiasma Pharmaceuticals Ltd. – which has since been acquired by Amryt Pharma Plc. (NASDQA: AMYT) – as Vice President of Preclinical Research where he headed preclinical development and pharmacology of oral octreotide through the NDA submission.

Shmuel earned his MSc and BSc degrees in biology from Tel-Aviv University, Israel, and his Ph.D. with Distinction at the Sackler School of Medicine.